Precigen (PGEN) Stock: Buy, Sell, or Hold?
PGEN - Precigen, Inc. Common Stock
$8.54
0.33 (4.02%)
▲
5d:
+10.19%
30d:
+21.83%
90d:
+52.5%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When PGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PGEN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PGEN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$30.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$19.17
55.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PGEN is currently trading at $8.54, which is considered extended relative to its 30-day fair value range of $6.89 to $7.93. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.5) compared to its historical average (33.9). Remarkably, the market is currently pricing in an annual earnings decline of 26.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $7.19, while resistance sits at $8.98. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: PGEN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.65 (+59.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $7.19, while resistance sits at $8.98. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: PGEN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.65 (+59.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.89 -
$7.93
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
Protect Your Profits
Holding PGEN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.7% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 59.8% below Wall St target ($13.65)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.89 -
$7.93
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.19
Resistance Level
$8.98
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.46
Wall Street Target
$13.65
(+59.8%)
Revenue Growth (YoY)
6322.7%
Profit Margin
-184.0%
Valuation Discount vs History
-26.5% cheaper
PE vs Historical
13.5 vs 33.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-26.5%
(market-implied from PE analysis)
1-Year Target
$7.69
(-10%)
2-Year Target
$6.92
(-19%)
3-Year Target
$6.23
(-27%)
3-Yr Target (if PE normalizes)
(PE: 13→34)
$15.68
(+84%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 184.8%)
$43.67
(+411%)
Base:
(SPY PE: 13.5, Growth: 184.8%)
$28.82
(+238%)
Bear:
(PE: 11.4, Growth: 184.8%)
$24.50
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.5 to 33.9
Stabilization Target:
$21.50
(+151.8%)
PE Expansion Potential:
+151.8%
Share & Embed Analysis
Last updated: October 03, 2026 11:52 PM ET
Data refreshes hourly during market hours. Next update: 12:52 AM
Data refreshes hourly during market hours. Next update: 12:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
Advanced PGEN Option Strategies
Professional options setups generated by AI based on today's PGEN price and gamma walls.
